Clinical Trial: Evaluating the Efficacy of Chidamide in Advanced Refractory Colorectal Cancer With High SULF1 Expression

U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07927075) titled 'Evaluating the Efficacy of Chidamide in Advanced Refractory Colorectal Cancer With High SULF1 Expression' on Nov. 04.

Brief Summary: Previous studies have shown that HDAC inhibitors can inhibit SULF1 expression in CAFs. Chidamide, an HDAC inhibitor widely used in clinical practice, has demonstrated good efficacy in advanced breast cancer. Our retrospective study found that the higher the proportion of breast cancer patients with high fibroblast SULF1 expression, the more effective chidamide treatment was. Currently, the third-line treatment for advanced colorectal cancer consists of oral regorafenib or fruquintinib, but their median...